Preprint
Efficacy of Lopinavir-Ritonavir Prophylaxis for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial
Abstract
Background: Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19.Methods: We conducted a pragmatic open-label, parallel, cluster-randomized superiority trial in four sites in Switzerland and Brazil. Clusters were randomized to receive LPV/r PEP (400/100 mg) twice daily for 5 days or no PEP …
Authors
Labhardt ND; Smit M; Petignat I; Perneger T; Marinosci A; Ustero P; Ribeiro MPD; Ragozzino S; Nicoletti GJ; Faré PB
Publication date
January 1, 2021
DOI
10.2139/ssrn.3878828
Preprint server
SSRN Electronic Journal